Malnutrition-Inflammation Complex Syndrome and Bone Fractures and Cardiovascular Disease Events in Patients Undergoing Hemodialysis: The Q-Cohort Study

Shunsuke Yamada, Hokuto Arase, Hisako Yoshida, Hiromasa Kitamura, Masanori Tokumoto, Masatomo Taniguchi, Hideki Hirakata, Kazuhiko Tsuruya, Toshiaki Nakano, and Takanari Kitazono

Rationale & Objective: Malnutrition-inflammation complex syndrome (MICS) is common in patients receiving hemodialysis and increases the risks of morbidity and mortality. However, few studies have examined the overall impact of MICS on disorders of the bone-cardiovascular axis.

Study Design: Prospective, multicenter, observational cohort study.

Setting & Participants: A total of 3,030 patients receiving maintenance hemodialysis registered in the Q-Cohort Study.

Predictors: A newly developed score for MICS composed of elements chosen from 8 baseline parameters related to nutrition and inflammation by bootstrap resampling, multivariable-adjusted Cox proportional hazard risk analysis for all-cause mortality, and the risk prediction rule. β-coefficients of each element analyzed in the multivariable-adjusted model were used for the creation of the MICS score.

Outcomes: Bone fractures, cardiovascular disease events, and the composite outcome of bone fractures and cardiovascular disease events.

Analytical Approach: Cox proportional hazard regression and Fine-Gray proportional subdistribution hazards regression.

Results: During a median follow-up of 4 years, 140 patients developed bone fractures and 539 developed cardiovascular disease events. Age; serum levels of creatinine, albumin, and C-reactive protein; and body mass index were selected for the creation of the MICS score. The median (IQR) MICS score was 196 (181-212). The multivariable-adjusted Cox proportional hazard risk model and the competing risk model showed that a higher MICS score was incrementally associated with elevated risks of bone fractures, cardiovascular disease events, and the composite outcome; hazard risks (95% CIs) of fractures, cardiovascular disease events, and the composite outcome for each 10-point increase in the MICS score were 1.18 (1.01-1.38), 1.16 (1.07-1.26), and 1.15 (1.07-1.24), respectively.

Limitations: One-time measurement of the parameters used for the creation of the MICS score.

Conclusions: Malnutrition and inflammation represented by the MICS score were associated with increased risks of bone-cardiovascular axis disorders in patients receiving maintenance hemodialysis.

Patients receiving hemodialysis are at extremely high risk of bone fractures and cardiovascular disease (CVD) events.1,12 Because bone fractures and CVD events increase the risks of morbidity, hospitalization, and mortality, both bone fractures and CVD events place huge public burdens on the hemodialysis population.1,13 Evidence has increasingly shown that the bone and cardiovascular systems form a tight link, share humoral mediators, and develop and maintain interdependently.1,6 Bone fractures and CVD events share risk factors, coexist in the same patients, and form a self-perpetuating cycle.1 Therefore, there is a need to identify modifiable and shared risk factors for this recently recognized bone-cardiovascular axis.

Patients receiving hemodialysis commonly have malnutrition and inflammation, and these conditions are closely associated with increased risks of all-cause and cardiovascular mortality.8,9 Basic studies have shown that malnutrition, inflammation, and oxidative stress in patients with uremia play critical roles in the pathogenesis of derangement in the cardiovascular system.10,11 To emphasize the close link among malnutrition, inflammation, and atherosclerosis-related cardiovascular diseases or comorbid conditions, the terms “malnutrition-atherosclerosis syndrome” and “malnutrition-inflammation complex syndrome (MICS)” have been proposed.8,9,12 Although serum markers of inflammation and malnutrition are associated with increased risks of bone fractures and CVD events, single markers fail to demonstrate the overall impact on the derangement in the bone-cardiovascular axis in patients receiving hemodialysis.13-17 Measurement of skeletal muscle mass by computed tomography, magnetic resonance imaging, dual-energy x-ray absorptiometry, or electrical bioimpedance analysis is another approach to evaluate nutritional status.18 Furthermore, a combination of several nutrition-related surrogate markers has been used in patients receiving hemodialysis, including the geriatric nutritional risk index, creatinine (Cr) index, and malnutrition-inflammation score (MIS).8,13,18-21 Importantly, some of these measures are subjective, semi-quantitative, and 1-sided, whereas others require special devices and experience and are expensive, not easily repeatable at the bedside, complex, and cumbersome.
To determine the overall impact of nutrition and inflammation on the bone-cardiovascular axis, we analyzed an existing dataset from a multicenter, prospective, observational study of patients in Japan undergoing hemodialysis. We developed a novel nutrition and inflammation scoring system and determined the association between each patient’s score and their risk of bone fractures and cardiovascular disease events. The scoring system consisted of age; serum levels of creatinine, albumin, and C-reactive protein; and body mass index. Patients experiencing malnourishment and inflammation had a higher score, which was associated with greater risk of bone fractures and cardiovascular disease events. Thus, our findings indicate that effective malnutrition and inflammation intervention is necessary to prevent bone fractures and cardiovascular disease events in patients undergoing hemodialysis.

The present study had 2 main aims. The first aim was to elucidate the overall impact of malnutrition and inflammation on the derangement in the bone-cardiovascular axis in patients receiving hemodialysis. The second aim was to develop an objective and multifaceted score for MICS that can be used for the overall evaluation of nutritional and inflammatory status of patients receiving hemodialysis that is simple, intuitive, objective, numeric, less expensive, repeatable at the bedside, applicable to a large population, and requires neither special devices nor experience.

The present study had 2 main aims. The first aim was to elucidate the overall impact of malnutrition and inflammation on the derangement in the bone-cardiovascular axis in patients receiving hemodialysis. The second aim was to develop an objective and multifaceted score for MICS that can be used for the overall evaluation of nutritional and inflammatory status of patients receiving hemodialysis. To achieve these aims, we analyzed the dataset in the Q-Cohort Study, a multicenter, prospective, observational study of patients receiving maintenance hemodialysis. The MICS score was developed by applying the bootstrapping technique, risk prediction rule, and multivariable-adjusted Cox proportional hazard model for all-cause mortality. The details of the statistical methods followed during the process of development, internal validation, and external validation of the MICS score are described in Item S1.

Outcomes and Exposure
The primary outcomes were bone fractures, CVD events, and the composite outcome of bone fractures and CVD events. The secondary outcome was all-cause mortality. The main exposure was the baseline MICS score, which was newly developed in the present study. Bone fractures were confirmed by radiological findings and clinical symptoms; not all patients with bone fractures required hospitalization. Asymptomatic vertebral fractures were not included. The CVD events included congestive heart failure requiring hospitalization, acute coronary syndrome (myocardial infarction with or without ST-segment elevation and unstable angina), and hemorrhagic and ischemic stroke. Arrhythmia requiring hospitalization and intervention for peripheral arterial disease were not included as CVD events in the present study. The CVD events were periodically assessed and confirmed by the central outcome review board members, who were representatives of the attending physicians at all dialysis facilities in the Q-Cohort Study.

Covariates and Biochemical Determination
The baseline characteristics and potential confounding factors were collected by reviewing the medical records. Routine biochemical parameters were measured with autoanalyzers using standard procedures. The details of the measurements and calculations used in the present study have been described elsewhere.

Development, Internal Validation, and External Validation of the MICS Score
The MICS score was developed by applying the bootstrapping technique, risk prediction rule, and multivariable-adjusted Cox proportional hazard model for all-cause mortality. The details of the statistical methods followed during the process of development, internal validation, and external validation of the MICS score are described in Item S1.

Statistical Analyses
Continuous variables were described as median (interquartile range), whereas categorical variables were expressed as number (percentage). Patients were divided from the analyses because of missing outcome data, and 441 patients were excluded because of insufficient information about baseline characteristics and medications. A total of 3,030 patients were finally included in the present analyses. The study was conducted under the Ethics of Clinical Research (Declaration of Helsinki). The Kyushu University Hospital Institutional Review Board for Clinical Research approved the protocol (no. 20-31), which was registered in the clinical trial registry (University Hospital Medical Information Network, UMIN000000556). All patients provided written informed consent before participating in the study.
into quartiles (Q1–Q4) based on the MICS score created in the present study. For comparison of the baseline characteristics across quartiles by the MICS score, trend analyses were performed using the Jonckheere-Terpstra test for continuous variables and the Cochran-Armitage test for categorical variables.

In the main analysis, we examined the association between the MICS score and the estimated risks of bone fractures, CVD events, and the composite outcome by using Cox proportional hazards models. Unadjusted and multivariable-adjusted models were used for the estimation of the hazard ratio (HR) and 95% confidence interval (CI). Multivariable-adjusted models included the following parameters as covariates: covariates 1 (age; sex; presence of diabetic nephropathy; history of cardiovascular disease events and bone fractures; hemodialysis vintage; hemodialysis time per session; Kt/V for urea; normalized protein catabolic rate; serum levels of urea nitrogen, cholesterol, corrected calcium, phosphate, alkaline phosphatase, and parathyroid hormone; and use of phosphate binders and vitamin D receptor activators) for bone fractures and covariates 2 (covariates 1 and cardiothoracic ratio, systolic blood pressure, blood hemoglobin level, and use of antihyper- tensives) for CVD events and the composite outcome. Additionally, the multivariable-adjusted nonlinear association between the MICS score and outcomes was plotted as HRs and 95% CIs, using restricted cubic spline curves with 4 knots and setting the association between the outcomes and a MICS score as the reference. As a sensitivity analysis, the Fine-Gray proportional subdistribution hazards models for the composite outcome by treating all-cause mortality as a competing risk were applied to consider potential competing risks.26 Also, to determine the age-independent impact of the MICS on the outcomes, association between the outcomes and a MICS score excluding age in the process of the score development was examined. Subgroup analysis by the baseline characteristics across quartiles by the MICS score was also conducted by setting the MICS score as a continuous variable and expressing the risks for the composite outcome as HRs (95% CIs) for every 10-point increase in the MICS score.

A 2-tailed P value of <0.05 was considered statistically significant unless otherwise specified. For the interaction term, a P value of <0.1 was considered statistically significant. Statistical analyses were performed using the JMP version 14.2 software (SAS Institute Inc), R version 4.0.2 (http://cran.rproject.org), and SAS software, version 9.4 (SAS Institute).

### RESULTS

#### Clinical Background Characteristics and Incidences of Outcomes

The clinical characteristics at baseline are summarized in Table 1. The median (interquartile range) of age was 64.4 (56.1-72.9) years, 59.2% of patients were women, and 28.7% had diabetic nephropathy as the primary kidney disease. During a median observation period of 4 years, 140 (4.6%) patients developed bone fractures, 539 (17.8%) developed CVD events, 645 (21.3%) developed the composite outcome of bone fractures and CVD events, and 499 (16.5%) died of any cause.

#### Development, Internal Validation, and External Validation of the MICS Score

The detailed process of development, internal validation, and external validation of the MICS score is described in Tables S1-S3 and Figs S1-S6. Briefly, the final selected components of the MICS score were age; body mass index (BMI); and serum levels of albumin, Cr, and C-reactive protein (CRP). The nomogram used to calculate the MICS score for each patient was created by applying the risk prediction rule for all-cause mortality and is shown in Fig 1. The distribution of the MICS score is shown in Fig 2.
The median (interquartile range) of the MICS score was 196 (181-212).

**Baseline Characteristics in Each Group Stratified by the MICS Score**

Table 2 shows the baseline characteristics of the 3,030 patients divided into quartiles based on the MICS score. Patients with a high MICS score were significantly older ($P < 0.05$), more likely to be men, had a significantly higher prevalence of diabetic nephropathy ($P < 0.05$), higher prevalence of a history of CVD events and bone fractures, shorter median dialysis history, shorter median dialysis time per session, and lower normalized protein catabolic rate and BMI. Patients with a higher MICS score had significantly lower blood hemoglobin levels and serum levels of albumin, total cholesterol, urea nitrogen, Cr, corrected calcium, phosphate, and parathyroid hormone ($P < 0.05$) and had significantly higher median serum CRP and alkaline phosphatase levels ($P < 0.05$). Phosphate binders and vitamin D receptor activators were less frequently used by patients with a higher MICS score.

---

**Figure 1.** Nomogram to calculate the malnutrition-inflammation complex syndrome score based on the risk prediction rule. Abbreviations: BMI, body mass index; Cr, creatinine; CRP, C-reactive protein.

**Figure 2.** Distribution of the MICS score (N = 3,030). Abbreviations: IQR, interquartile range; MICS, malnutrition-inflammation complex syndrome; N, number.
Incidences of Outcomes in Each Quartile Based on the MICS Score

The numbers of patients who developed bone fractures, CVD events, and the composite outcome in the 4 groups stratified by the MICS score are shown in Table 3. Patients with a higher MICS score showed significantly higher incidences of bone fractures, CVD events, and the composite outcome ($P < 0.05$).

Association Between the MICS Score and the Risks of Bone Fractures, CVD Events, and the Composite Outcome

Figure 3 shows the unadjusted Kaplan-Meier curves for bone fractures, CVD events, and the composite outcome in patients grouped into quartiles based on the MICS score. Patients with a higher MICS score showed a lower event-free survival than those with a lower MICS score (log-rank $P$ value $< 0.05$). The multivariable-adjusted Cox proportional hazard risk model analysis showed that the risks for bone fractures, CVD events, and the composite outcome significantly and incrementally increased in tandem with the MICS score (Table 4). Similar results were obtained even when the MICS score was treated as a continuous variable and the risks for these outcomes were evaluated by every 10-point increase in the MICS score: 1.18 (1.01-1.38), 1.16 (1.07-1.26), and 1.15 (1.07-1.24), respectively (Table 4). Furthermore, restricted cubic spline curve analyses also showed that a higher MICS score was marginally associated with increased risks of bone fractures and significantly associated with increased risks of CVD events and composite outcome (Fig 4).

Notably, even taking the competing risk of all-cause mortality into account, the association between the MICS score and the risk of the composite outcome remained statistically significant (Table 5). The multivariable-adjusted HR (95% CI) for every 10-point increase in the MICS score was 1.16 (1.07-1.25) ($P < 0.001$).

---

**Table 2. Baseline Characteristics in Each Quartile Based on the MICS Score at Baseline (N = 3,030)**

| Baseline Characteristics | Quartiles Stratified by the Baseline MICS Score | P for Trend |
|--------------------------|-----------------------------------------------|------------|
|                          | Q1: 116-181 | Q2: 182-196 | Q3: 197-211 | Q4: 212-294 |
| Basic information         | n = 777    | n = 753     | n = 775     | n = 725     |
| Age, y                   | 50.9 (43.0-57.0) | 61.0 (56.9-65.8) | 68.5 (63.9-73.2) | 77.4 (71.9-81.9) | <0.001 |
| Sex (male), n (%)        | 422 (54.3%) | 439 (58.3%) | 495 (63.9%) | 438 (60.4%) | 0.002 |
| Diabetic nephropathy, n (%) | 130 (16.7%) | 234 (31.1%) | 278 (35.9%) | 229 (31.6%) | <0.001 |
| History of cardiovascular diseases, n (%) | 136 (17.5%) | 252 (33.5%) | 307 (39.6%) | 343 (47.3%) | <0.001 |
| History of bone fractures, n (%) | 39 (5.0%) | 54 (7.2%) | 70 (10.1%) | 130 (17.9%) | <0.001 |
| Dialysis vintage, y     | 7.2 (3.5-13.2) | 6.7 (2.6-13.1) | 4.6 (1.8-10.8) | 3.8 (1.2-8.7) | <0.001 |
| Dialysis time per session, h | 5.0 (4.5-5.0) | 5.0 (4.5-5.0) | 5.0 (4.5-5.0) | 4.5 (4.0-5.0) | <0.001 |
| Single-pool Kt/V for urea | 1.56 (1.40-1.75) | 1.56 (1.39-1.73) | 1.56 (1.42-1.72) | 1.56 (1.42-1.73) | 0.69 |
| Normalized protein catabolic rate, g/kg/d | 0.97 (0.90-1.08) | 0.95 (0.85-1.05) | 0.95 (0.84-1.04) | 0.90 (0.78-0.98) | <0.001 |
| Body mass index, kg/m²  | 21.7 (19.5-24.0) | 21.5 (19.4-23.6) | 20.8 (19.1-23.1) | 19.4 (17.8-21.3) | <0.001 |
| Cardiothoracic ratio    | 48.6 (45.9-51.8) | 50.0 (47.0-53.2) | 50.6 (47.3-54.2) | 52.2 (48.2-56.3) | <0.001 |
| Systolic blood pressure, mm Hg | 152 (136-167) | 154 (140-169) | 154 (140-168) | 152 (136-168) | 0.53 |

**Blood tests results**

| Blood hemoglobin, g/dL | 10.6 (10.0-11.4) | 10.7 (10.0-11.4) | 10.5 (9.8-11.2) | 10.3 (9.5-11.0) | 0.001 |
| Serum albumin, g/dL    | 4.1 (3.9-4.3) | 3.9 (3.7-4.1) | 3.8 (3.6-4.0) | 3.4 (3.2-3.7) | <0.001 |
| Serum total cholesterol, mg/dL | 155 (133-182) | 153 (133-182) | 153 (131-179) | 146 (124-167) | <0.001 |
| Serum C-reactive protein, mg/dL | 0.10 (0.03-0.20) | 0.13 (0.09-0.24) | 0.13 (0.07-0.30) | 0.22 (0.10-0.80) | <0.001 |
| Serum urea nitrogen, mg/dL | 72 (63-82) | 68 (59-77) | 65 (56-74) | 60 (50-69) | <0.001 |
| Serum creatinine, mg/dL  | 12.6 (10.9-14.3) | 10.8 (9.4-12.1) | 9.5 (8.2-11.1) | 8.0 (6.7-9.3) | <0.001 |
| Albumin-corrected serum calcium, mg/dL | 9.4 (8.9-9.9) | 9.5 (8.9-9.9) | 9.3 (8.9-9.8) | 9.3 (8.9-9.8) | 0.010 |
| Serum phosphate, mg/dL   | 5.3 (4.5-6.1) | 5.0 (4.4-5.8) | 4.8 (4.1-5.5) | 4.4 (3.8-5.2) | <0.001 |
| Serum alkaline phosphatase, U/L | 206 (161-277) | 229 (180-313) | 239 (185-308) | 260 (211-345) | <0.001 |
| Serum PTH (intact assay), pg/mL | 119 (55-243) | 108 (49-216) | 105 (49-212) | 83 (39-159) | <0.001 |

**Medications**

| Use of antihypertensive drugs, n (%) | 477 (61.4%) | 506 (67.2%) | 498 (64.3%) | 455 (62.8%) | 0.84 |
| Use of phosphate binders, n (%)     | 715 (92.0%) | 666 (88.4%) | 625 (80.6%) | 473 (65.2%) | <0.001 |
| Use of VDRA, n (%)                   | 586 (75.4%) | 540 (71.7%) | 560 (72.3%) | 461 (63.8%) | <0.001 |

Note: Baseline data are expressed as median (interquartile range) for continuous variables and number (percentage) for categorical variables. The Cochran-Armitage test was used to determine $P$ values for trends of categorical variables, whereas the Jonckheere-Terpstra test was used to determine $P$ values for trends of continuous variables. A 2-tailed $P$ value of $<0.05$ was considered statistically significant. Conversion factors for units: serum calcium in mg/dL to mmol/L, $× 0.2495$; serum creatinine in mg/dL to μmol/L, $× 0.357$; serum phosphate in mg/dL to mmol/L, $× 0.3229$; serum total cholesterol in mg/dL to mmol/L, $× 0.2495$; serum albumin, g/dL to mg/dL, $× 0.3229$. Abbreviations: MICS, malnutrition-inflammation complex syndrome; PTH, parathyroid hormone; Q, quartile by the MICS score; VDRA, vitamin D receptor activator.
Table 3. Number of Events in Each Quartile Based on the MICS Score (N = 3,030)

|                        | Total (N = 3,030) | Quartiles Based on the MICS Score | P for Trend |
|------------------------|-------------------|-----------------------------------|-------------|
|                        |                    | Q1: 116-181 (n = 777)             |             |
| Bone fractures         | 140 (4.6%)        | 19 (2.5%)                         |             |
|                        |                    | Q2: 182-196 (n = 753)             |             |
|                        | 539 (17.8%)        | 69 (8.9%)                         |             |
| CVD events             | 645 (21.3%)        | 87 (11.2%)                        |             |
|                        |                    | Q3: 197-211 (n = 775)             |             |
|                        | 182 (5.3%)         | 150 (19.9%)                       |             |
| Composite outcome      | 499 (16.5%)        | 74 (9.8%)                         |             |
|                        |                    | Q4: 212-294 (n = 725)             |             |
| All-cause death        | 45 (6.2%)          | 137 (17.7%)                       | <0.001      |
|                        | 49 (1.6%)          | 264 (36.4%)                       |             |

Note: Data are expressed as number (percentage) in each group. The Cochran-Armitage test was used to determine P values for trends of categorical variables. In the analysis of the composite outcome, the first event was counted when the same patients developed both bone fractures and CVD events during the observation period. A P value of <0.05 was considered statistically significant.

Abbreviations: CVD, cardiovascular disease; MICS, malnutrition-inflammation complex syndrome; Q, quartile by the MICS score.

**Figure 3.** Unadjusted Kaplan-Meier analyses for the outcomes among patients stratified by the MICS score quartiles. (A) Bone fractures. (B) CVD events. (C) Composite outcome. Log-rank test was used to determine the statistical significance. A 2-tailed P value of <0.05 was considered statistically significant. Abbreviations: CVD, cardiovascular disease; MICS, malnutrition-inflammation complex syndrome.
Effect Modifications by Baseline Characteristics
Regarding the Association of the MICS Score With the Composite Outcome

When patients were divided into 2 groups based on the various baseline characteristics and the effect modifications were analyzed, the impact of the MICS score on the composite outcome was significantly augmented in patients without diabetic nephropathy as the primary kidney disease (P < 0.1). There were no significant interactions between the other baseline characteristics and the MICS score regarding the composite outcome (Fig 5).

Age-Independent Impact of the MICS Score on the Outcomes

To determine the age-independent impact of the nutritional and inflammatory statuses on the outcomes, we also developed a MICS score with age excluded as a potential component of the score development. In the development of the new MICS score without age, the parameters selected as components of the score were the serum levels of urea nitrogen, Cr, albumin, and CRP and the BMI. We then created another nomogram based on the same methods used in the creation of the age-included MICS score. When the MICS score without age was applied to the 3,030 patients undergoing hemodialysis, the MICS score without age was marginally associated with an increased risk of bone fractures and significantly associated with elevated risks of CVD events and the composite outcome (Table S4). The multivariable-adjusted HR (95% CI) for these outcomes evaluated by every 10-point increase in the MICS score were 1.27 (1.04-1.55), 1.21 (1.09-1.34), and 1.19 (1.10-1.28), respectively.

DISCUSSION

Literature review suggests that both chronic inflammation and malnutrition are associated with the increased risks of morbidities. However, it remains unknown whether the bone-cardiovascular axis is disordered in patients receiving maintenance hemodialysis. In the present study, we demonstrated for the first time the overall impact of malnutrition and inflammation on the derangement in the bone-cardiovascular axis by developing a new score for MICS and analyzing the association between the MICS score and the risk of bone fractures, CVD events, and the composite outcome in patients receiving maintenance hemodialysis. The MICS score was composed of age; serum levels of Cr, albumin, and CRP; and BMI by applying the bootstrapping technique, risk prediction rule, and multivariable-adjusted Cox proportional hazard model for all-cause mortality. Our results suggest that patients
undergoing hemodialysis with a higher MICS score are at greater risk of derangement in the bone-cardiovascular axis, followed by increased incidences of CVD events and bone fractures, probably resulting in decreased activity of daily living, reduced quality of life, and augmented risk of mortality.

The tight link between inflammation, malnutrition, and derangement of the bone-cardiovascular axis requires

Figure 4. Multivariable-adjusted restricted cubic spline plots of hazard ratios (HRs) for the outcomes. (A) Bone fractures. (B) CVD events. (C) Composite outcome. Solid lines represent HRs, whereas dotted lines represent 95% confidence intervals. Horizontal gray lines correspond to the reference HR (1.0). The median MICS score of 196 was chosen as the reference value. Covariates used in the multivariable model are described in the Methods section. A 2-tailed $P$ value of $<0.05$ was considered statistically significant. Abbreviations: CVD, cardiovascular disease; MICS, malnutrition-inflammation complex syndrome.

Table 5. Association Between the MICS Score and Composite Outcome Analyzed by the Competing Risk Model (N = 3,030)

| Outcomes | Unadjusted Model | Multivariable-adjusted Model |
|----------|-----------------|-------------------------------|
|          | HR (95% CI)     | $P$ Value | $P$ for Trend | HR (95% CI)     | $P$ Value | $P$ for Trend |
| Q1; 116-181 | 1 (reference) |           |             | 1 (reference) |           |             |
| Q2; 182-196 | 1.89 (1.45-2.47) | $<0.001$ | $<0.001$ | 1.30 (0.97-1.74) | 0.08 | 0.01 |
| Q3; 197-211 | 2.57 (1.99-3.31) | $<0.001$ |             | 1.49 (1.08-2.06) | 0.02 |         |
| Q4; 212-294 | 4.06 (3.16-5.21) | $<0.001$ |             | 1.97 (1.32-2.93) | $<0.001$ |         |
| Every 10 score increase in the MICS score | 1.27 (1.23-1.32) | $<0.001$ |             | 1.16 (1.07-1.25) | $<0.001$ |         |

Note: HRs and 95% CIs for the composite outcome were estimated by the Fine-Gray subdistribution hazard regression model by treating all-cause mortality as the competing risk. In the multivariable-adjusted analysis for the composite outcome, the covariates were age, sex, presence of diabetic nephropathy, history of cardiovascular disease events and bone fractures, hemodialysis vintage, hemodialysis time per session, Kt/V for urea, normalized protein catabolic rate, cardiothoracic ratio, systolic blood pressure, blood hemoglobin levels, serum levels of urea nitrogen, total cholesterol, corrected calcium, phosphate, alkaline phosphatase, and parathyroid hormone, and use of antihypertensive drugs, phosphate binders, and vitamin D receptor activators. A 2-tailed $P$ value of $<0.05$ was considered statistically significant. Abbreviations: CI, confidence interval; HR, hazard ratio; MICS, malnutrition-inflammation complex syndrome; Q, quartile based on the MICS score.
elucidation. One reasonable mechanistic explanation for the observed associations may be that the risk factors for bone fractures and CVD events are shared in the bone-cardiovascular axis. Indeed, epidemiologic studies have shown that aging, hypertension, dyslipidemia, diabetes mellitus, oxidative stress, inflammation, and uremic milieu collectively accelerate the development and progression of osteoporosis and atherosclerosis/arteriosclerosis in chronic kidney disease.\textsuperscript{3,7,27,28} In particular, inflammatory cytokines, including interleukin 1, interleukin 6, and tumor necrosis factor \( \alpha \), decrease bone strength by accelerating bone resorption and promoting atherosclerosis and arteriosclerosis.\textsuperscript{29,31} Furthermore, malnutrition increases the risk of bone fractures through sarcopenia and deficiencies of vitamin D and protein and promotes CVD events via altered cellular metabolism in hemodialysis. We have recently shown that patients with decreased skeletal muscle mass and those with decreased protein intake have increased risks of bone fractures and CVD events.\textsuperscript{16,32,33} These results indicate the importance of managing shared risk factors to prevent bone fractures and CVD events in patients undergoing hemodialysis.

![Figure 5](#)

| Age | Younger (<65 years old) | Older (≥65 years old) |
|-----|-------------------------|-----------------------|
| No. of Events | 242 | 1571 |
| No. of Patients | 403 | 1459 |

| Sex | Woman | Man |
|-----|-------|-----|
| 250 | 1236 |
| 395 | 1794 |

| Presence of diabetic nephropathy | Absence | Presence |
|---------------------------------|---------|----------|
| 385 | 2159 |
| 260 | 871 |

| History of CVDs | Absence | Presence |
|-----------------|---------|----------|
| 292 | 1992 |
| 353 | 1038 |

| History of bone fractures | Absence | Presence |
|---------------------------|---------|----------|
| 554 | 2729 |
| 91 | 301 |

| Dialysis vintage | Shorter (<5 years) | Longer (≥5 years) |
|------------------|------------------|------------------|
| 304 | 1425 |
| 341 | 1605 |

| Systolic blood pressure | Lower (<135 mmHg) | Higher (≥135 mmHg) |
|-------------------------|-------------------|-------------------|
| 286 | 1503 |
| 359 | 1527 |

| Serum albumin | Lower (<3.8 g/dL) | Higher (≥3.8 g/dL) |
|---------------|------------------|------------------|
| 323 | 1294 |
| 322 | 1736 |

| Serum creatinine | Lower (<10.3 mg/dL) | Higher (≥10.3 mg/dL) |
|------------------|---------------------|---------------------|
| 370 | 1514 |
| 385 | 1659 |

| Serum C-reactive protein | Lower (<0.13 mg/dL) | Higher (≥0.13 mg/dL) |
|-------------------------|---------------------|---------------------|
| 260 | 1371 |
| 385 | 1659 |

| Body mass index | Lower (<20.8 kg/m\(^2\)) | Higher (≥20.8 kg/m\(^2\)) |
|-----------------|--------------------------|--------------------------|
| 316 | 1492 |
| 329 | 1538 |

| nPCR | Lower (<0.96 g/kg/day) | Higher (≥0.96 g/kg/day) |
|------|------------------------|------------------------|
| 393 | 1819 |
| 252 | 1211 |

| Serum calcium | Lower (<9.5 mg/dL) | Higher (≥9.5 mg/dL) |
|---------------|-------------------|-------------------|
| 335 | 1632 |
| 310 | 1398 |

| Serum phosphate | Lower (<4.9 mg/dL) | Higher (≥4.9 mg/dL) |
|-----------------|-------------------|-------------------|
| 342 | 1482 |
| 303 | 1548 |

| Serum PTH (intact assay) | Lower (<102 pg/mL) | Higher (≥102 pg/mL) |
|-------------------------|-------------------|-------------------|
| 331 | 1504 |
| 314 | 1526 |

| Use of antihypertensive agents | No | Yes |
|-------------------------------|----|-----|
| 195 | 1094 |
| 450 | 1936 |

| Use of phosphate-binders | No | Yes |
|------------------------|----|-----|
| 126 | 551 |
| 519 | 2479 |

| Use of VDRAs | No | Yes |
|--------------|----|-----|
| 204 | 883 |
| 441 | 2147 |

| No. of Patients | Decrease in risk | HR (95% CI) | Increase in risk | HR (95% CI) | P-value |
|-----------------|-----------------|-------------|-----------------|-------------|---------|
| 0               | 1               | 2           | 0               | 1           | 2       |

| Effect | Interaction |
|-------|-------------|
| 1.13  | (1.02-1.26) |
| 0.01  | 0.77        |
| 1.20  | (1.11-1.30) |
| <0.001| 0.04        |

Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; MICS, malnutrition-inflammation complex syndrome; nPCR, normalized protein catabolic rate; PTH, parathyroid hormone; VDRA, vitamin D receptor activator.
Another explanation may be that the health of the bone and cardiovascular systems is interdependent and that degraded bone health promotes cardiovascular diseases, whereas damaged cardiovascular organs impair bone strength and quality via shared humoral mediators; this phenomenon has recently been called the bone-cardiovascular axis. For example, osteoprotegerin, a decoy receptor of the receptor activator of nuclear kappa ligand, is expressed and secreted by the vascular cells and affects bone remodeling. The C-type natriuretic peptide is excreted from endothelial cells and has an impact on bone cells. In turn, the bone-forming cells excrete a variety of mediators (including calciprotein particles, sclerostin, and fibroblast growth factor 23), which act on vascular cells and alter the pathophysiology of atherosclerosis and arteriosclerosis. These results suggest that the health of the bone and cardiovascular systems is partly maintained through humoral mediators. In addition, bone volume is regulated by the blood supply, and arteriosclerosis causes ischemic osteopathy in patients with advanced peripheral artery disease. Further studies are necessary to determine whether interventions for malnutrition or treatment for inflammation reduce the risk of bone fractures and CVD events and to develop effective dietary and pharmacological approaches for the prevention of the derangement in the bone-cardiovascular axis in patients receiving hemodialysis.

The newly developed MICS score was composed of 5 elements: age; serum levels of albumin, Cr, and CRP; and BMI. The definition of protein-energy wasting proposed by the International Society for Renal Nutrition and Metabolism includes the following categories: serum biochemistry, body mass, muscle mass, and dietary protein intake. Our MICS score covered 3 of these 4 categories, indicating that the MICS score was consistent with the global guidelines. The new MICS score also included serum CRP level as a marker of inflammatory status. The serum CRP level provides different information than the serum albumin level and might increase the sensitivity for MICS detection. Importantly, our MICS score correlated well with the geriatric nutritional risk index and Cr index (Fig S5), which are pre-established nutritional indexes used worldwide. Furthermore, the internal and external validities of the MICS score were acceptably high (Figs S4 and S6). These results suggest that the MICS score could be useful for the assessment of nutritional and inflammatory status in patients receiving hemodialysis and for the prediction of clinically relevant outcomes. However, because aging is closely related to the development of both malnutrition and clinically relevant outcomes (including bone fractures and CVD events), the current MICS score that included age as a component may underestimate the association of malnutrition and inflammation with the outcomes. Notably, based on our sensitivity analysis, even when age was excluded from the MICS score, the age-independent MICS score was significantly correlated with increased risks of bone fractures, CVD events, and the composite endpoint (Table S4). These results suggest that malnutrition and inflammation are associated with the derangement of the bone-cardiovascular axis independently of age in patients undergoing hemodialysis.

Although the MIS is a more comprehensive tool to evaluate MICS and is regarded as the gold standard, some of the parameters used in the MIS (such as the subjective global assessment) are subjective and thus yield large interobserver differences; furthermore, the MIS requires the serum transferrin level, which is not routinely measured in the daily management of the hemodialysis population. Importantly, the selection of each component of the MIS is based on the clinical experience, whereas the components of our MICS score were determined using a scientific approach; furthermore, the cutoff values of each of the 10 components in the MIS are not based on the relative impact of each component on the nutritional status or other outcomes, although the MIS has been consequently associated with various clinically important outcomes in patients undergoing hemodialysis. In contrast, our MICS score requires age, BMI, and serum markers routinely measured in the clinical setting. In addition, the MICS score appears to be more objective than the MIS and provides a relatively high reproducibility. Indeed, the advocate of the MIS has mentioned that the MIS is not always the gold standard for the assessment of malnutrition and inflammation. Furthermore, we have confirmed that the discriminative performance and calibration of the newly developed MICS score were acceptable. Overall, these findings suggest that our MICS score may help to stratify the risk of various outcomes in the hemodialysis population. In future studies, our MICS score should be compared with the MIS regarding the predictability of various clinically relevant outcomes in patients undergoing hemodialysis.

In the subgroup analysis, the impact of the MICS score on the composite outcome was augmented in patients without diabetic nephropathy. Because diabetes mellitus has been shown to accelerate the deterioration in the bone and cardiovascular system by hyperglycemia, advanced glycation endproducts, and increased oxidative stress and inflammation, the impact of malnutrition on the bone-cardiovascular axis may be relatively weakened in patients with diabetic nephropathy. The potential interaction between diabetes mellitus and the MICS score regarding the bone-cardiovascular axis requires further examination in future studies.

The strengths of our study were its relatively large sample size, long observational period, and multivariable adjustment with a variety of baseline data, including medication. The present study had several limitations. First, because there is no gold standard measure to allocate a patient into a binary variable reflecting whether they are well-nourished or malnourished, we regressed the potential candidate parameters that were reportedly associated with nutritional status and inflammation to all-cause...
mortality. Second, we assessed the status of malnutrition and inflammation only at the baseline. Because the nutritional status changed during the observation period, we were unable to eliminate the possibility of misclassification bias. Third, because the current study included prevalent patients undergoing hemodialysis rather than incident patients undergoing hemodialysis, the findings derived from our cohort might be affected by survivor bias.\textsuperscript{44,45} Namely, patients with good nutritional status survived and were included in the cohort, and these patients had a longer dialysis vintage than those with malnutrition at baseline. However, even when patients were stratified by dialysis vintage, the associations between the MICS score and the outcomes were not altered. Fourth, because we had no available data to calculate the MIS, we could not compare the predictive performance between the MICS score and the MIS. Fifth, because of the observational nature of the study, we were unable to discuss the causality between the degree of malnutrition and inflammation and outcomes. Sixth, although we rigorously adjusted for confounding factors, we were unable to eliminate the possibility that the unmeasured and residual confounding factors might have biased the association observed in the present study. Hence, the results of the current study should be cautiously interpreted and require further confirmation in future well-designed studies.

In conclusion, we developed an objective score reflecting the concept of MICS in patients receiving hemodialysis and showed that malnutrition and inflammatory status determined by the MICS score was strongly associated with increased risks of bone fractures, CVD events, and the composite outcome in patients undergoing hemodialysis. Further studies are necessary to determine whether interventions for malnutrition and inflammation can decrease the incidence of events related to the deterioration of the bone-cardiovascular axis in patients receiving hemodialysis.

**SUPPLEMENTARY MATERIAL**

**Supplementary File 1 (PDF)**

**Figure S1**: The calculation formula for the risk prediction model of the MICS score.

**Figure S2**: Simplified scoring system for calculating the MICS score using multiple cutoff values.

**Figure S3**: Internal validation of the MICS score (n = 3,030).

**Figure S4**: External validation of the MICS score for the predictive performance and calibration using an independent hemodialysis cohort (n = 153).

**Figure S5**: Correlation between the MICS score and pre-established nutritional indexes. (A) Correlation between the MICS score and GNRI. (B) Correlation between the MICS score and Cr index. Pearson's correlation coefficients were calculated, and coefficients of determination (R\textsuperscript{2}) are described. A 2-tailed P value of <0.05 was considered statistically significant. Abbreviations: Cr, creatinine; GNRI, geriatric nutritional risk index; MICS, malnutrition-inflammation complex syndrome.

**Figure S6**: Comparison of the AUROCs for all-cause mortality among the models by the MICS score, GNRI, and Cr index (n = 3,030). (A) Comparison of the MICS score and GNRI. (B) Comparison of the MICS score and Cr index. A P value of <0.05 was considered statistically significant. The AUROC (=Harrel's C-statistics) was calculated by univariable Cox proportional hazard regression analysis with one of the nutritional parameters (MICS score, GNRI, or Cr index). Abbreviations: AUROC, area under the receiver operating characteristics curve; Cr, creatinine; GNRI, geriatric nutritional risk index; MICS, malnutrition-inflammation complex syndrome.

**ITEM S1**: Supplementary Patients and Methods.

**ITEM S2**: Supplementary Results.

**Table S1**: Frequencies of the Potential Candidate Parameters Chosen in the Process of the MICS Score Creation by Bootstrap Resampling and Cox Proportional Hazard Risk Analysis

**Table S2**: Baseline Characteristics of the Independent Hemodialysis Cohort (n = 153).

**Table S3**: Baseline Characteristics of the Independent Hemodialysis Cohort Stratified by Quartiles Based on the MICS Score (n = 153).

**Table S4**: Association Between the MICS Score Without Age and Outcomes Analyzed by the Cox Proportional Hazard Risk Model (n = 3,030).

**ARTICLE INFORMATION**

**Authors' Full Names and Academic Degrees**: Shunsuke Yamada, MD, PhD; Hokuto Arase, MD; Hisaako Yoshida, PhD; Hiromasa Kitamura, MD; Masanori Tokumoto, MD, PhD; Masatomo Taniguchi, MD, PhD; Hideki Hirakata, MD, PhD; Kazuhiro Tsuruya, MD, PhD; Toshiaki Nakano, MD, PhD; and Takanari Kitazono, MD, PhD

**Authors’ Affiliations**: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan (SY, HA, HK, TN, TK); Department of Medical Statistics, Osaka City University Graduate School of Medical Sciences, Osaka, Japan (HY); Department of Internal Medicine, Fukuoka Dental College, Fukuoka, Japan (MTo); Fukuoka Renal Clinic, Fukuoka, Japan (MTa, HH); and Department of Nephrology, Nara Medical University, Nara, Japan (KT).

**Address for Correspondence**: Toshiaki Nakano, MD, PhD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 8128582, Japan. Email: toshink@med.kyushu-u.ac.jp

**Authors’ Contributions**: Research idea and study design: SY, HA, MTo; data acquisition: SY, MTa, TN, KT; data analysis interpretation: SY, HA, HY, HK, MTo, MTa; statistical analysis: SY, HY, HK; supervision or mentorship: HH, TN, KT, TK. Each author contributed important intellectual content during manuscript drafting and accepts accountability for the overall work by ensuring that questions about the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

**Support**: The Q-Cohort Study is supported by The Kidney Foundation, Japan (H19 JKF 07-13, H20 JKF 08-8, H23 JKF 11-11), and the Japan Dialysis Outcome Research Foundation (H19-076-02 and H20-003), without restriction on publications.

**Financial Disclosure**: Dr Tokumoto has received honoraria and consulting fees from Kyowa Hakko Kirin and Ono Pharmaceutical. Dr Taniguchi has received honoraria and consulting fees from Kyowa Hakko Kirin and Torii Pharmaceutical Co, Ltd. Dr Hirakata has received honoraria and consulting fees from Kyowa Hakko Kirin and Torii Pharmaceutical Co, Ltd. Dr Tsuruya has received...
honorary, consulting fees, and/or grant/research support from Chugai Pharmaceutical Co, Kyowa Hakko Kirin, Bayer Yakuin, Fuso Pharmaceutical, and Torii Pharmaceutical Co, Ltd. Dr Nakano has received honorary, consulting fees, and/or grant/research support from Chugai Pharmaceutical Co, Kyowa Hakko Kirin, Bayer Yakuin, Fuso Pharmaceutical, and Torii Pharmaceutical Co, Ltd. Dr Kitazono has received honorary, consulting fees, and/or grant/research support from Mitsubishi Tanabe Pharma Co; Takeda Pharmaceutical Co, Ltd; Pfizer Japan Inc; Eizai Co, Ltd; Merck Sharp and Dohme; Astellas Pharma Inc; Novartis Pharma; Kyowa Hakko Kirin Co, Ltd; Daichii Sankyo Co, Ltd; Otsuka Pharmaceutical Co, Ltd; Nippon Boehringer Ingelheim Co, Ltd; Torii Pharmaceutical Co, Ltd; Bristol-Myers Squibb K.K.; Sumitomo Dainippon Pharma Co, Ltd; Sanofi-Aventis K.K.; Chugai Pharmaceutical Co, Ltd; Bayer Yakuin, Ltd; Ono Pharmaceutical Co, Ltd; Taisho Toyama Pharmaceutical Co, Ltd; Fuso Pharmaceutical Industries, Ltd; Novo Nordisk Pharm, Ltd; Teijin Pharma, Ltd; Toray Medical Co, Ltd; Abbvie GK; AstraZeneca K.K.; and Asahi Kasei Medical Co, Ltd. Drs Yamada, Arase, Yoshida, and Kitamura declare that they have no relevant financial interests.

Acknowledgements: We express our sincere thanks to all the doctors and medical staff who participated in the Q-Cohort Study. The following personnel (institutions) participated in this study: Takashi Ando (Hakozaki Park Internal Medicine Clinic); Takashi Ariyoshi (Ariyoshi Clinic); Kouichiro Goto (Goto Clinic); Fumitada Hattori (Nagao Hospital); Harumichi Higashi (St Mary’s Hospital); Tadashi Hirano (Hakujyuji Hospital); Kei Hori (Munakata Medical Association Hospital); Takashi Inenaga (Kisakakei Moji Hospital); Hitotoshi Kanai (Kokura Memorial Hospital); Shigemi Kyama (Kyama Naika); Tetsuo Komoto (Komoto Clinic); Hiromasa Kuma (Kuma Clinic); Toshiro Maeda (Kozenkai-Maeda Hospital); Junichi Makino (Makino Clinic); Dai Matsuo (Hirao Clinic); Chiaki Mishima (Mishima Naika Clinic); Koji Mitsuki (Japanese Red Cross Hospital); Kenichi Motomura (Motomura Naika Clinic); Sadatoshi Nakamura (Kokura Daichi Hospital); Hitotoshi Nakamura (Kokura Daichi Hospital); Kochi Nakashima (Ohashi Internal Circulatory Clinic); Nobumitsu Okita (Shiryoishi Kyoritsu Hospital); Shinichiro Osato (Osato Jin Clinic); Sakurako Sakamoto (Fujiyama Spa Hospital); Keiko Shigematsu (Shigematsu Clinic); Kazumasa Shimamatsu (Shimamatsu Naika In); Yoshito Shogakiuchi (Shin-Ai Clinic); Hiroaki Takamura (Hara Hospital); Kazuhiro Takeda (Izuka Hospital); Asuka Terai (Chidoribashi Hospital); Hideyoshi Tanaka (Mojiko-Jin Clinic); Suguru Tomooka (Hakozaki Park Internal Medicine Clinic); Tito Toyonaga (Fukuoka Renal Clinic); Hiroshi Tsuruta (Steel Memorial Yayawata Hospital); Ryutaro Yamaguchi (Shiseikai Hospital); Taihei Yanagida (Saiseikai Yahata General Hospital); Tetsuro Yanase (Yanase Internal Medicine Clinic); Tetsuhiko Yoshida (Hamanomachi Hospital); Takahiro Yoshimitsu (Gofukumachi Kidney Clinic, Harasanshin Hospital); and Koji Yoshitomi (Yoshitomi Medical Clinic). We thank Kelly Zammit, BVSc, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

Peer Review: Received March 16, 2021. Evaluated by 2 external peer reviewers, with direct editorial input by an Associate Editor, a Statistical Editor, and the Editor-in-Chief. Accepted in revised form November 14, 2021.

REFERENCES

1. Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. *Kidney Int*. 2014;85(1):166-173.
2. Himmelstarr J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int*. 2002;62(5):1524-1538.
3. Honda H, Oureshi AR, Heimbürger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *Am J Kidney Dis*. 2006;47(1):139-148.
4. London GM. Bone-vascular cross-talk. *J Nephrol*. 2012;25(5):619-625.
5. Seifert ME, Hruska KA. The kidney-vascular-bone axis in the chronic kidney disease-mineral bone disorder. *Transplantation*. 2016;100(3):497-505.
6. Evenepoel P, Opdebeck B, David K, D’Haese PC. Bone-vascular axis in chronic kidney disease. *Adv Chronic Kidney Dis*. 2019;26(6):472-483.
7. Viena L, Behets GJ, Heye S, et al. Inflammation and the bone-vascular axis in end-stage renal disease. *Osteoporoos Int*. 2016;27(2):489-497.
8. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. *Am J Kidney Dis*. 2001;38(6):1251-1263.
9. Stenvinkel P, Heimbürger O, Lindholm B, Kayser GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). *Nephrol Dial Transplant*. 2000;15(7):953-960.
10. Yamada S, Tokumoto M, Tatsumoto N, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. *Am J Physiol Renal Physiol*. 2014;306(12):F1418-F1428.
11. Yamada S, Taniguchi M, Tokumoto M, et al. The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. *J Bone Miner Res*. 2012;27(2):474-485.
12. Zhang K, Gao J, Chen J, et al. MICS, an easily ignored contributor to arterial calcification in CKD patients. *Am J Physiol Renal Physiol*. 2016;311(4):F663-F670.
13. Takahashi H, Ishii H, Aoyama T, et al. Association of cardiac valvular calcifications and C-reactive protein with cardiovascular mortality in incident hemodialysis patients: a Japanese cohort study. *Am J Kidney Dis*. 2013;61(2):254-261.
14. Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. *Am J Kidney Dis*. 2002;40(2):307-314.
15. Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. *Osteoporos Int*. 2012;23(4):1191-1198.
16. Yamada S, Taniguchi M, Tokumoto M, et al. Modified creatinine index and the risk of bone fracture in patients undergoing hemodialysis: the Q-Cohort Study. *Am J Kidney Dis*. 2017;70(2):270-280.
17. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int*. 2006;70(7):1358-1366.
18. Lopes AA, Bragg-Gresham JL, Elder SJ, et al. Independent and joint associations of nutritional status indicators with mortality risk among chronic hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *J Ren Nutr*. 2010;20(4):224-234.
19. Stenvinkel P, Gillespie IA, Tunks J, et al. Inflammation modifies the paradoxical association between body mass index and mortality in hemodialysis patients. *J Am Soc Nephrol*. 2016;27(5):1479-1486.
20. Yamada S, Yamamoto S, Fukuma S, Nakano T, Tsuyura K, Inaba M. Geriatric Nutritional Risk Index (GNRI) and Creatinine
32. Ohnaka S, Yamada S, Tsujikawa H, et al. Association of the malnutrition-inflammation score in assessment of nutritional risk and lifestyle habits in haemodialysis patients. *Nephrol Dial Transplant.* 2010;25(8):2662-2671.

22. Tanaka S, Ninomiya T, Taniguchi M, et al. Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in haemodialysis patients: the Q-Cohort Study. *Nephrol Dial Transplant.* 2016;31(7):1152-1160.

21. Beberashvili I, Azar A, Sinuani I, et al. Objective Score of Nutrition on Dialysis (OSND) as an alternative for the malnutrition-inflammation score in assessment of nutritional risk in haemodialysis patients. *Kidney Med.* 2020;10(1):5756.

20. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammation, muscle strength, and risk of falls in older adults: the Health, Aging and Body Composition Study. *J Am Geriatr Soc.* 2002;(80):103-108.

19. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? *Nephrol Dial Transplant.* 2013;28(11):2670-2677.

18. Noordzij M, Leffondr e K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. Inflammation, nutrition, and cardiovascular events have increased osteoblasts, bone mass and bone strength. *Bone.* 2020;135:115320.

17. Jimbo R, Kawakami-Mori F, Mu S, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. *Kidney Int.* 2014;85(5):1103-1111.

16. Klingensmith G, Tchiderer L, Himmler G, et al. Associations of serum Dickkopf-1 and sclerostin with cardiovascular events: results from the prospective Bruneck study. *J Am Heart Assoc.* 2020;9(6):e014816.

15. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int.* 2008;73(4):391-398.

14. Mukai H, Villafuerte H, Qureshi AR, Lindholm B, Stenvinkel P. Serum albumin, inflammation, and nutrition in end-stage renal disease: C-reactive protein is needed for optimal assessment. *Semin Dial.* 2018;31(5):435-439.

13. Arase H, Yamada S, Yotsueda R, et al. Modified creatinine index and risk for cardiovascular events and all-cause mortality in patients undergoing hemodialysis: the Q-Cohort study. *Atherosclerosis.* 2018;275:115-123.

12. Golleh J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. *Stroke.* 2004;35(7):1641-1647.

11. Robinson JW, Blixt NC, Norton A, et al. Male mice with elevated C-type natriuretic peptide-dependent guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength. *Bone.* 2020;135:115320.

10. Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. *Ther Apher Dial.* 2013;17(3):247-288.

9. Noordzij M, Leffondre K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? *Nephrol Dial Transplant.* 2013;28(2):217-225.

8. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. *Br Med J.* 1973;4(5893):643-646.

7. Gaudio A, Xourafa A, Zanoli L, et al. Early vascular ageing biomarkers in osteoporotic outpatients: a pilot study. *Sci Rep.* 2020;10(1):19421.

6. Szekanecz Z, Rateman HG, Pethö Z, Lems WF. Common mechanisms and holistic care in atherosclerosis and osteoporosis. *Arthritis Res Ther.* 2019;21(1):15.

5. Gaudio A, Xourafa A, Zanoli L, et al. Early vascular ageing biomarkers in osteoporotic outpatients: a pilot study. *Sci Rep.* 2020;10(1):19421.

4. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? *Kidney Int Suppl.* 2002;(80):103-108.

3. McLean RR. Proinflammatory cytokines and osteoporosis. *Curr Osteoporos Rep.* 2009;7(4):134-139.

2. Ohnaka S, Yamada S, Tsujikawa H, et al. Association of normalized protein catabolic rate (nPCR) with the risk of bone fracture in patients undergoing maintenance hemodialysis: the q-cohort study. *Clin Nutr.* 2021;40(3):997-1004.
### Methods and Cohort

Prospective, multicenter, observational cohort study in Japan.

Patients receiving maintenance HD, N = 3,003.

Dec 2006 – Dec 2007

---

### Exposure

| MICS score | Q1: 116 – 181 n = 777 | Q2: 182 – 196 n = 753 | Q3: 197 – 211 n = 775 | Q4: 212 – 294 n = 725 | Every 10-score increase in the MICS score (HR, 95% CI) |
|------------|------------------------|------------------------|------------------------|------------------------|--------------------------------------------------|
| Fractures  | 2.5% 1.18 (1.01 - 1.39) | 4.6% 1.16 (1.07 - 1.26) | 5.3%                   | 6.2%                   |                                                  |
| CVEs       | 8.9% 1.15 (1.07 - 1.24) | 16.3%                  | 20.9%                  | 25.5%                  |                                                  |
| Composite outcome | 11.1%     | 18.9%                  | 22.6%                  | 28.7%                  |                                                  |
| All-cause death | 3.1%  P < 0.001 | 9.8%  P < 0.001 | 17.7%  P < 0.001 | 36.4%  P < 0.001 |                                                  |

HD, hemodialysis; MICS, malnutrition-inflammation complex syndrome; Q, quartile by the MICS score; CVEs, cardiovascular disease events

---

### Results

**Conclusion:** Malnutrition and inflammation represented by the MICS score were associated with increased risks of bone-cardiovascular axis disorders in patients receiving maintenance hemodialysis.

**Reference:** Yamada S, Arase H, Yoshida H et al. Malnutrition-inflammation complex syndrome (MICS) and bone fractures and cardiovascular events in patients undergoing hemodialysis: The Q-cohort study. *Kidney Medicine*, 2022.

Visual Abstract by Denise Arellano, MD @denise_am